XENE (Xenon Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

XENE (Xenon Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

Mkt Cap$5B

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Revenue (TTM)$8M

Net Income (TTM)-$346M

EPS (TTM)-$4.36

Free Cash Flow (TTM)-$280M

Gross Margin-944.0%

Op. Margin-4974.3%

Net Margin-4612.1%

FCF Margin-3732.2%

P/S Ratio (TTM)622.4x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$49M
Q2 23	$0	$0	-$56M
Q3 23	$0	$0	-$56M
Q4 23	$0	$0	-$54M
Q1 24	$0	-$599K	-$59M
Q2 24	$0	$0	-$69M
Q3 24	$0	$0	-$74M
Q4 24	$0	$0	-$77M
Q1 25	$8M	$8M	-$73M
Q2 25	$0	-$632K	-$94M
Q3 25	$0	-$77M	-$96M
Q4 25	$0	-$611K	-$110M

Valuation

Quarter	P/S	P/E
Q1 23	6987.6x	—
Q2 23	35361.5x	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	622.4x	—
Q2 25	622.4x	—
Q3 25	622.4x	—
Q4 25	622.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$34M	-$37M
Q2 23	-$33M	-$35M
Q3 23	-$42M	-$43M
Q4 23	-$35M	-$36M
Q1 24	-$46M	-$46M
Q2 24	-$33M	-$34M
Q3 24	-$50M	-$50M
Q4 24	-$54M	-$55M
Q1 25	-$62M	-$62M
Q2 25	-$64M	-$64M
Q3 25	-$72M	-$72M
Q4 25	-$81M	-$82M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$2M
Q3 23	$1M
Q4 23	$78K
Q1 24	$188K
Q2 24	$2M
Q3 24	$590K
Q4 24	$783K
Q1 25	$43K
Q2 25	$157K
Q3 25	$281K
Q4 25	$318K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-100.0%	+87.7%
Q2 23	-100.0%	+80.3%
Q3 23	-100.0%	+45.5%
Q4 23	—	+23.9%
Q1 24	—	+20.4%
Q2 24	—	+24.2%
Q3 24	—	+32.3%
Q4 24	—	+44.3%
Q1 25	—	+35.9%
Q2 25	—	+36.4%
Q3 25	—	+30.8%
Q4 25	—	+41.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	—
Q2 23	$8M	—
Q3 23	$9M	—
Q4 23	$9M	—
Q1 24	$9M	—
Q2 24	$15M	—
Q3 24	$13M	—
Q4 24	$14M	—
Q1 25	$12M	162.3%
Q2 25	$14M	—
Q3 25	$14M	—
Q4 25	$14M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$40M	$10M
Q2 23	$44M	$12M
Q3 23	$43M	$13M
Q4 23	$41M	$13M
Q1 24	$44M	$15M
Q2 24	$50M	$19M
Q3 24	$57M	$17M
Q4 24	$59M	$18M
Q1 25	$61M	$19M
Q2 25	$75M	$19M
Q3 25	$77M	$19M
Q4 25	$88M	$22M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$70M	$458M	$527M
Q2 23	$65M	$475M	$540M
Q3 23	$100M	$427M	$527M
Q4 23	$149M	$489M	$638M
Q1 24	$59M	$641M	$700M
Q2 24	$137M	$585M	$722M
Q3 24	$88M	$566M	$654M
Q4 24	$143M	$484M	$627M
Q1 25	$117M	$433M	$550M
Q2 25	$135M	$352M	$488M
Q3 25	$105M	$358M	$462M
Q4 25	$199M	$350M	$549M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	66M	+0.1%
Q2 23	66M	+0.2%
Q3 23	66M	+0.2%
Q4 23	70M	+6.0%
Q1 24	78M	+10.9%
Q2 24	78M	+0.1%
Q3 24	78M	+0.3%
Q4 24	78M	+0.6%
Q1 25	79M	+0.4%
Q2 25	79M	+0.3%
Q3 25	79M	+0.4%
Q4 25	79M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$535K	53
FY 15	$188K	83
FY 16	$19K	94
FY 17	$4K	81
FY 18	$0	92
FY 19	$66K	104
FY 20	$249K	129
FY 21	$121K	153
FY 22	$44K	213
FY 23	$0	259
FY 24	$0	327
FY 25	$750	10K